Status: Not yet recruiting
Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary
This study is a single-arm, open-label, multicenter Phase II clinical trial designed to observe and evaluate the efficacy and safety of Pucotenlimab in combination with MRG002 in patients with HER2-positive (IHC 2+ or 3+) cancer of unknown primary.
Participants needed: 50
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Zhiguo Luo, MD, PhDUpdated: Mar 12, 2025Locations: 1
Eligibility criteria
Voluntarily sign the informed consent form and comply with the protocol requirem... [+10]
History of other primary malignancies. [+11]